Prevaccination Study of Cervical Human Papillomavirus Types in Yangtze River Delta Area, China
NCT01487681 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4000
Last updated 2011-12-07
Summary
Human papilloma virus (HPV) infection contributes as a main causative factor to the development of invasive cervical cancer (ICC) and its precursors (cervical intraepithelial neoplasia, CIN). Currently, two prophylactic vaccines are employed for the prevention of genital HPV infection. As the prophylactic efficacy is type-restricted, determining the type-specific HPV distribution and their associations with ICC and its precursors would provide essential information in assessment of HPV vaccination program impact. The baseline information is also important for monitoring possible changes in type-specific HPV distribution after vaccination has been introduced.
Prevalence of HPV infection varies considerably across the world, and data were limited from less-developed countries. Knowledge of the detail pattern of HPV type-specific distribution in each region will be essential for public health policy decisions. This will also form the basis for determining which types should be included in future generation HPV vaccines targeted to specific regions.
While most studies were focus on ICC and high-grade cervical lesions, the association between HPV types and the progression of CIN1 has rarely been studied. CIN1 is an insensitive histopathological sign of HPV infection, most of which will spontaneously regress to normal with host immune system. However, some genotypes have been described as being more persistent and associated with progression from low-grade lesions to high-grade lesions, even ICC. Geographical data on type-specific prevalence of HPV in CIN1 with appropriately designed prospective studies would be helpful in identifying types preferentially associated with progression to malignancy and accurately predicting the future impact of vaccination in specific regions.
Free vaccination supported by the government appears to be unlikely at present in China. Thus, individuals need to pay the cost of vaccines for themselves presently. Yangtze River Delta Area is the most economically developed regions in China, and people here may become the largest vaccinated population at their own expense in China. To the best of the investigators knowledge, no multi-center study on HPV type-specific distribution and their associations with ICC and its precursors is available in Yangtze River Delta Area, China, which highlights the need for timely study in this region before large scale vaccination programs are carried out.
Conditions
- Human Papilloma Virus
- Cervical Cancer
- Cervical Intraepithelial Neoplasia
Sponsors & Collaborators
-
Xing Xie, MD
lead OTHER
Principal Investigators
-
Xing Xie, Professor · Women's Hospital School Of Medicine Zhejiang University
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-11-30
- Primary Completion
- 2012-10-31
- Completion
- 2013-10-31
Countries
- China
Study Locations
More Related Trials
-
A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
NCT05282745 ·Status: RECRUITING
-
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528 ·Status: RECRUITING
-
Protective Efficacy of HPV Vaccination After Treatment of HPV Related Diseases
NCT05085093 ·Status: UNKNOWN
-
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
NCT01021904 ·Status: UNKNOWN ·Phase: PHASE4
-
DNA Methylation and the Increased Risk of Cervical Cancer Development
NCT06859151 ·Status: NOT_YET_RECRUITING
-
HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study
NCT04694495 ·Status: COMPLETED
-
Longitudinal HPV Pap in CIN and VAIN
NCT05931354 ·Status: UNKNOWN
-
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
NCT05300243 ·Status: UNKNOWN
-
Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia
NCT04274465 ·Status: COMPLETED
-
Knowledge, Attitude &practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
NCT06743880 ·Status: NOT_YET_RECRUITING
-
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
NCT04574635 ·Status: ACTIVE_NOT_RECRUITING
-
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00054041 ·Status: COMPLETED ·Phase: PHASE2
-
Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment
NCT04743674 ·Status: RECRUITING
-
Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort
NCT02774538 ·Status: COMPLETED ·Phase: NA
-
Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines
NCT07077980 ·Status: NOT_YET_RECRUITING
-
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
NCT03548740 ·Status: UNKNOWN
-
Cervical Cancer Screening Strategies
NCT05309122 ·Status: UNKNOWN
-
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
NCT05950087 ·Status: RECRUITING
-
Multiple Human Papillomavirus Infections in the Development of CIN
NCT06862102 ·Status: RECRUITING
-
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
NCT01328028 ·Status: COMPLETED
-
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
NCT05531981 ·Status: UNKNOWN
-
Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
NCT00601601 ·Status: COMPLETED
-
Accurate Screening and Prevention of Cervical Lesions-- Development of Accurate Screening Methods for Cervical Lesions
NCT05851079 ·Status: UNKNOWN
-
Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests
NCT05536843 ·Status: UNKNOWN
-
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
NCT00019110 ·Status: COMPLETED ·Phase: PHASE1